- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody Therapy for Pediatric Leukemia
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 4, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2014-04-21
DOI
10.3389/fonc.2014.00082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
- (2014) Anjali S. Advani et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2013) V. Ribrag et al. CLINICAL CANCER RESEARCH
- The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
- (2013) H. Carol et al. CLINICAL CANCER RESEARCH
- Analytical and bioanalytical technologies for characterizing antibody–drug conjugates
- (2013) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Inactivation of theCdkn2alocus cooperates withHMGA1to drive T-cell leukemogenesis
- (2013) Francescopaolo Di Cello et al. LEUKEMIA & LYMPHOMA
- DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
- (2013) D. Li et al. MOLECULAR CANCER THERAPEUTICS
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD19 in B-cell lymphoma: emerging role of SAR3419
- (2013) Ayad Al-Katib et al. Cancer Management and Research
- Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
- (2013) Mark Chao Cancer Management and Research
- Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives
- (2013) Chiara F. Magnani et al. Frontiers in Oncology
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
- (2012) H. Hasle et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma
- (2012) Myron S. Czuczman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- Late Effects of Acute Lymphoblastic Leukemia Therapy in Patients Diagnosed at 0-20 Years of Age
- (2011) L. L. Robison Hematology-American Society of Hematology Education Program
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- (2010) Michinori Ogura et al. CANCER SCIENCE
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
- (2010) A. S. Wayne et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Investigational antibody-drug conjugates for hematological malignancies
- (2010) Andrew G Polson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia
- (2010) Andrea Meinhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
- (2010) R Handgretinger et al. LEUKEMIA
- Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
- (2010) A G Polson et al. LEUKEMIA
- Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
- (2009) A. M. Al-Katib et al. CLINICAL CANCER RESEARCH
- Use of tumour-responsive T cells as cancer treatment
- (2009) Mary L Disis et al. LANCET
- A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report
- (2009) Anne L. Angiolillo et al. PEDIATRIC BLOOD & CANCER
- Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy
- (2008) José Carlos Jaime-Pérez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Approved monoclonal antibodies for cancer therapy
- (2008) Michael Boyiadzis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
- (2008) Patrice Chevallier et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group
- (2008) Richard Aplenc et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study
- (2008) Elizabeth A. Raetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg
- (2008) Ka-Chun Cheung et al. LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search